Serum levels of anti-cyclic citrullinated peptide antibodies are associated with a beneficial response to traditional herbal medicine (Kampo) in rheumatoid arthritis

Rheumatology International

Volumn 29, Issue 12, 2009, Pages 1441-1447

  Kogure, Toshiaki ^a,c   Sato, Hiroko ^a   Kishi, Daijiro ^a   Ito, Tomoyuki ^b   Tatsumi, Takeshi ^a  

^a GUNMA UNIVERSITY   (Japan)

^b NAGAOKA RED CROSS HOSPITAL   (Japan)

^c NONE   (Japan)

Author keywords

Anti cyclic citrullinated peptide antibody; Predictor; Responder; Rheumatoid arthritis; Traditional herbal medicine

Indexed keywords

BUCILLAMINE; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; KAMPO; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; SALAZOSULFAPYRIDINE; TACROLIMUS; TUMOR NECROSIS FACTOR ANTIBODY;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; TREATMENT RESPONSE;

AGED; ANTIBODIES, ANTI-IDIOTYPIC; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; DRUGS, CHINESE HERBAL; FOLLOW-UP STUDIES; HUMANS; MEDICINE, KAMPO; MIDDLE AGED; PEPTIDES, CYCLIC; PREDICTIVE VALUE OF TESTS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 69049104114     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-009-0877-8     Document Type: Article

References (23)

1. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines 2002 Guidelines for the management of rheumatoid arthritis: 2002 update Arthritis Rheum 46 328 346 10.1002/art.10148
2. T Kogure A Hoshino K Ito H Sato T Tatsumi Y Ohyama E Kawata K Fujita J Tamura 2005 Beneficial effect of complementary alternative medicine on lymphedema with rheumatoid arthritis Mod Rheumatol 15 445 449 10.1007/s10165-005-0438-2
3. A Niizawa T Kogure LX Hai H Fujinaga K Takahashi Y Shimada K Terasawa 2003 Clinical and immunomodulatory effects of fun-boi, an herbal medicine, on collagen-induced arthritis in vivo Clin Exp Rheumatol 21 57 62
4. A Niizawa T Kogure H Fujinaga K Takahashi Y Shimada K Terasawa 2000 Clinical and immunomodulatory effects of fun-boi, an herbal medicine, in rheumatoid arthritis J Clin Rheumatol 6 244 249 10.1097/00124743-200010000-00002
5. JAM Wessels SM van der Kooij S le Cessie W Kievit P Barerra CF Allaart TWJ Huizinga H-J Guchelaar 2007 A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent onset rheumatoid arthritis Arthritis Rheum 56 1765 1775 10.1002/art.22640
6. Kogure T, Tatsumi T, Fujinaga H, Niizawa A, Terasawa K (2007) Insights to clinical use of serial determination in titers of cyclic citrullinated peptide autoantibodies. Mediators Inflamm 2007:12367 [Epub 2007 Mar 7]
7. M Hoekstra AE van Ede CJ Haagsma MAFJ van de Laar TWJ Huizinga MWM Kruijsen RFJM Laan 2003 Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis Ann Rheum Dis 62 423 426 10.1136/ard.62.5.423
8. S Kaltenhäuser M Pierer S Arnold M Kamprad C Baerwald H Häntzschel U Wagner 2007 Antibodies against cyclic citrullinated peptide are associated with the DRB1 shared epitope and predict joint erosion in rheumatoid arthritis Rheumatology (Oxford) 46 100 104 10.1093/rheumatology/ kel052
9. R Sghiri E Bouagina H Zaglaoui H Mestiri L Harzallah I Harrabi M Ghannouchi F Mokhtar I Ghedira 2007 Diagnostic performances of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis Rheumatol Int 27 1125 1130 10.1007/s00296-007-0351-4
10. FC Arnett SM Edworthy DA Bloch DJ Mcshane JF Fries NS Cooper LA Healey SR Kaplan MH Liang HS Luthra TA Medsger Jr DM Mitchell DH Neustadt RS Pinals JG Schaller JT Sharp RL Wilder GG Hunder 1988 The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis Arthritis Rheum 31 315 324 10.1002/art.1780310302
11. Terasawa K (1993) Introduction. In: Terasawa K (ed) KAMPO Japanese-oriental medicine; insights from clinical cases. K.K. Standard McIntyre, Tokyo, pp 1-13
12. H Yamanaka Y Tanaka N Sekiguchi E Inoue K Saito H Kameda N Iikuni M Nawata K Amano M Shinozaki T Takeuchi 2007 Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan Mod Rheumatol 17 28 32 10.1007/s10165-006- 0532-0
13. T Pincus A Larsen RH Brooks J Kaye EP Nance LF Callahan 1997 Comparison of 3 quantitative measures of hand radiographs in patients with rheumatoid arthritis: Steinbrocker stage, Kaye modified Sharp score, and Larsen score J Rheumatol 24 2106 2112
14. GR Komatireddy RW Leitch K Cella G Browning M Minor 1997 Efficacy of low load resistive muscle training in patients with rheumatoid arthritis functional class II and III J Rheumatol 24 1531 1539
15. NG Papadopoulos GZ Tsiaousis A Pavlitou-Tsiontsi A Giannakou VK Galanopoulou 2008 Does the presence of anti-CCP autoantibodies and their serum levels influence the severity and activity in rheumatoid arthritis patients? Clin Rev Allergy Immunol 34 11 15 10.1007/s12016-007-8018-1
16. K Ogawa T Kojima C Matsumoto S Kamegai T Oyama Y Shibagaki H Muramoto T Kawasaki H Fujinaga K Takahashi H Hikiami H Goto C Kiga K Koizumi H Sakurai Y Shimada M Yamamoto K Terasawa S Takeda I Saiki 2007 Identification of a predictive biomarker for the beneficial effect of a Kampo (Japanese traditional) medicine keishibukuryogan in rheumatoid arthritis patients Clin Biochem 40 1113 1121 10.1016/j.clinbiochem.2007.06.005
17. K Visser KN Verpoort H van Dongen SM van der Kooij CF Allaart RE Toes TW Huizinga AH n Mil 2008 Pretreatment serum levels of anti-cyclic citrullinated peptide antibodies are associated with the response to methotrexate in recent-onset arthritis Ann Rheum Dis 67 1194 1195 10.1136/ard.2008.088070
18. A Spadaro V Riccieri 2005 Methotrexate effect on anti-cyclic citrullinated peptide antibody levels in rheumatoid arthritis Ann Rheum Dis 64 1241 1242 10.1136/ard.2004.032136
19. L De Rycke X Verhelst E Kruithof F Van den Bosch IE Hoffman EM Veys F De Keyser 2005 Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis Ann Rheum Dis 64 299 302 10.1136/ard.2004.023523
20. P Caramaschi D Biasi E Tonolli S Pieropan N Martinelli A Carletto A Volpe LM Bambara 2005 Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment Rheumatol Int 26 58 62 10.1007/s00296-004-0571-9
21. C Alessandri M Bombardieri N Papa M Cinquini L Magrini A Tincani G Valesini 2004 Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNF-alpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement Ann Rheum Dis 63 1218 1221 10.1136/ard.2003.014647
22. MM Ahmed E Mubashir RE Wolf S Hayat V Hall R Shi SM Berney 2006 Impact of treatment with infliximab on anticyclic citrullinated peptide antibody and rheumatoid factor in patients with rheumatoid arthritis South Med J 99 1209 1215
23. Meyer O, Nicaise-Roland P, Santos MD, Labarre C, Dougados M, Goupille P, Cantagrel A, Sibilia J, Combe B (2006) Serial determination of cyclic citrullinated peptide autoantibodies predicted five-year radiological outcomes in a prospective cohort of patients with early rheumatoid arthritis. Arthritis Res Ther 8:R40 [Epub]. doi: 10.1186/ar1896